Y-mAbs Therapeutics, Inc. (YMAB)

Revenue by Product

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Novel Antibody-based Therapeutic Products	85.19M
Novel Antibody-based Therapeutic Products Growth	1.03%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
United States	65.98M
United States Growth	-2.70%
Eastern Asia	7.46M
Latin America	4.72M
Western Asia	4.05M
Western Europe	2.09M
Other Regions	890.00K
Other Regions Growth	-94.61%